|
Sep 5
|
Protagonist Therapeutics to Present at Upcoming Investor Conferences
|
|
Aug 9
|
Protagonist Receives $34 Million from Warrant Exercises
|
|
Jul 5
|
Protagonist Therapeutics-Janssen Partnered Psoriasis Candidate Fall Short Of Rival Treatment
|
|
Jul 4
|
Protagonist Therapeutics Announces Positive Topline Results with JNJ-2113, the First and Only Oral IL-23 Receptor Antagonist Peptide in Development for Moderate-to-Severe Plaque Psoriasis
|
|
Jun 30
|
Protagonist Therapeutics (PTGX) Is a Great Choice for 'Trend' Investors, Here's Why
|